APX Ophthalmology

Company Overview

Snapshot

Founded in October 2011 by Elie Eliachar and Ehud Assia, APX Ophthalmology operates with 1–10 employees. The company holds a patent for its technology. In May 2024, APX Ophthalmology ceased operations.

Business overview

APX Ophthalmology develops a pupil dilation and expansion device designed for use in ophthalmic surgical procedures. The company's core product is a scissor-like device with blunt, rounded terminal tips and a Nitinol spring, engineered for easy insertion and removal without impeding surgical instruments. This technology aims to provide effective pupil dilation, comfortable surgical performance, and a high safety profile for surgeons managing small pupils or floppy iris syndrome. APX Ophthalmology operates within the Health Tech & Life Sciences sector, specifically focusing on Medical Devices and Medical Treatment & Therapeutics for healthcare providers.

Strategic signal

APX Ophthalmology ceased operations in May 2024. This indicates a complete halt in the company's activities and product development, signaling to investors and innovation teams that the venture is no longer active in the market.

Company Intelligence Q&A

What is APX Ophthalmology's primary product?

APX Ophthalmology's primary product is a pupil dilation and expansion device designed to facilitate cataract surgery and other ophthalmic procedures in patients with small pupils or floppy iris syndrome.

When was APX Ophthalmology founded?

APX Ophthalmology was founded in October 2011.

Who are the founders of APX Ophthalmology?

APX Ophthalmology was co-founded by Elie Eliachar and Ehud Assia.

What is the current operational status of APX Ophthalmology?

APX Ophthalmology ceased operations in May 2024.

What is the core technology behind APX Ophthalmology's device?

The core technology is a scissor-like pupil dilator and expander featuring blunt, rounded terminal tips on the internal side and a Nitinol spring on the outer side, designed for efficient and safe surgical use.